Artwork

Sisällön tarjoaa Science Changing Life and Scripps Research. Science Changing Life and Scripps Research tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

Episode 34 – Travis Young: Finding a cure for cancer with novel immunotherapies

29:49
 
Jaa
 

Manage episode 394318124 series 1908208
Sisällön tarjoaa Science Changing Life and Scripps Research. Science Changing Life and Scripps Research tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Dr. Travis Young is the Vice President of Biologics at Calibr, the drug discovery and development division of Scripps Research. Travis and the team have created a new type of immunotherapy called “switchable” chimeric antigen receptor (CAR) T-cell therapy, which is already delivering precise and powerful therapies to patients with the most difficult to treat cancers. Listen as we talk about reengineering an individual’s immune T cells, promising clinical trials in leukemia and lymphoma patients, and using similar approaches to treat autoimmune diseases. Show notes: Episode transcript: https://www.scripps.edu/_files/images/2022_images/podcast-images/Travis-Young-transcript.pdf Travis and his colleagues discuss ongoing therapies being developed at Calibr during the Front Row lecture series https://www.youtube.com/watch?v=WRzQniqUlHo&t=2625s Preliminary results of switchable CAR-T cells in lymphoma patients https://www.scripps.edu/news-and-events/press-room/2021/20211208-calibr-announces-clinical-data-car-t-cells.html Tweet: @CARTCellTherapy Explore the Scripps Research Magazine https://magazine.scripps.edu/ Subscribe to receive our monthly e-newsletter https://signup.e2ma.net/signup/1879047/1890109/ @scrippsresearch on Twitter
  continue reading

52 jaksoa

Artwork
iconJaa
 
Manage episode 394318124 series 1908208
Sisällön tarjoaa Science Changing Life and Scripps Research. Science Changing Life and Scripps Research tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Dr. Travis Young is the Vice President of Biologics at Calibr, the drug discovery and development division of Scripps Research. Travis and the team have created a new type of immunotherapy called “switchable” chimeric antigen receptor (CAR) T-cell therapy, which is already delivering precise and powerful therapies to patients with the most difficult to treat cancers. Listen as we talk about reengineering an individual’s immune T cells, promising clinical trials in leukemia and lymphoma patients, and using similar approaches to treat autoimmune diseases. Show notes: Episode transcript: https://www.scripps.edu/_files/images/2022_images/podcast-images/Travis-Young-transcript.pdf Travis and his colleagues discuss ongoing therapies being developed at Calibr during the Front Row lecture series https://www.youtube.com/watch?v=WRzQniqUlHo&t=2625s Preliminary results of switchable CAR-T cells in lymphoma patients https://www.scripps.edu/news-and-events/press-room/2021/20211208-calibr-announces-clinical-data-car-t-cells.html Tweet: @CARTCellTherapy Explore the Scripps Research Magazine https://magazine.scripps.edu/ Subscribe to receive our monthly e-newsletter https://signup.e2ma.net/signup/1879047/1890109/ @scrippsresearch on Twitter
  continue reading

52 jaksoa

Kaikki jaksot

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas

Kuuntele tämä ohjelma tutkiessasi
Toista